New cases of progressive multifocal leukoencephalopathy after treatment with natalizumab

The Lancet Neurology

Volumn 8, Issue 1, 2009, Pages 28-31

  Hartung, Hans Peter ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; BETA1A INTERFERON; CYCLOPHOSPHAMIDE; EFALIZUMAB; GADOLINIUM; MEFLOQUINE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NATALIZUMAB; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; VERY LATE ACTIVATION ANTIGEN 4; VIRUS DNA;

DRUG MECHANISM; HUMAN; IMMUNOADSORPTION; JC VIRUS; LETTER; MONOTHERAPY; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PLASMAPHERESIS; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RISK BENEFIT ANALYSIS;

ADULT; ANTIBODIES, MONOCLONAL; AZATHIOPRINE; FEMALE; HUMANS; INTERFERON-BETA; LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL; MAGNETIC RESONANCE IMAGING; MALE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING;

EID: 57149117126     PISSN: 14744422     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1474-4422(08)70281-3     Document Type: Letter

References (22)

1. Ransohoff R.M. Natalizumab for multiple sclerosis. N Engl J Med 356 (2007) 2622-2629
2. US Food and Drug Administration. Natalizumab (marketed as Tysabri) Information. http://www.fda.gov/Cder/drug/infopage/natalizumab (accessed November 4, 2008).
3. Baldinetti F., Belcher G., Bozic C., et al. Natalizumab utilization and safety: latest results from TOUCH and TYGRIS. Eur J Neurol 15 (2008) 27-28 Abstract SC317.
4. Kleinschmidt-DeMasters B.K., and Tyler K.L. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med 353 (2005) 369-374
5. Langer-Gould A., Atlas S.W., Green A.J., et al. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 353 (2005) 375-381
6. Van Assche G., Van Ranst M., Sciot R., et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med 353 (2005) 362-368
7. Yousry T.A., Major E.O., Ryschkewitsch C., et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med 354 (2006) 924-933
8. Kappos L., Bates D., Hartung H.P., et al. Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring. Lancet Neurol 6 (2007) 431-441
9. Falco V., Olmo M., Villar del Saz S., et al. Influence of HAART on the clinical course of HIV-1-infected patients with progressive multifocal leukoencephalopathy: results of an observational multicenter study. J Acquir Immune Defic Syndr 49 (2008) 26-31
10. Marzochetti A., Di Giambenedetto S., Cingolani A., et al. Reduced rate of diagnostic detection of JC virus DNA in cerebrospinal fliud in cases of suspected progressive multifocal leukoencephalopathy in the era of potent antiretroviral therapy. J Clin Microbiol 43 (2005) 4175-4177
11. Iacobaeus E., Ryschkewitsch C., Gravell M., et al. Analysis of cerebrospinal fluid and cerebrospinal fluid cells from patients with multiple sclerosis for detection of JC virus DNA. Mult Scler (2008) 10.1177/1352458508096870 published online September 19.
12. O'Connor P.W., Goddman A., Kappos L., et al., for the AFFIRM and SENTINEL Investigators. Results of clinical and magnetic resonance imaging analyses following cessation of natalizumab dosing in patients with multiple sclerosis. Mult Scler 12 (2006) S14
13. Stüve O., Marra C.M., Bar-Or A., et al. Altered CD4/CD8-T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis. Arch Neurol 63 (2006) 1383-1387
14. Venkataramana A., Pardo C.A., McArthur J.C., et al. Immune reconstitution inflammatory syndrome in the CNS of HIV-infected patients. Neurology 67 (2006) 383-388
15. Du Pasquier R.A., Kuroda M.J., Zheng Y., et al. A prospective study demonstrates an association between JC virus-specific cytotoxic T lymphocytes and the early control of progressive multifocal leukoencephalopathy. Brain 127 (2004) 1970-1978
16. Zohren F., Toutzaris D., Klärner V., et al. The monoclonal anti-VLA-4 antibody natalizumab mobilizes CD34+ hematopoietic progenitor cells in humans. Blood 111 (2008) 3893-3895
17. Krumbholz M., Meinl I., Kümpfel T., et al. Natalizumab disproportionately increases circulating pre-B and B cells in multiple sclerosis. Neurology 71 (2008) 1350-1354
18. Boren E.J., Gurtej S.C., Naguwa S.M., et al. The emergence of progressive multifocal leukoencephalopathy (PML) in rheumatic diseases. J Autoimm 30 (2008) 90-98
19. Hartmann E.A., and Huang D. Update on PML: lessons from the HIV uninfected and new insights in pathogenesis and treatment. Current HIV/AIDS Reports 5 (2008) 112-119
20. Hemmer B., Frohmann E., Hartung H.P., and Stüve O. Central nervous system infections-a potential complication of systemic immunotherapy. Curr Opin Neurol 19 (2006) 271-276
21. The US Food and Drug Administration. 2008 Safety Alerts for Human Medical Products (Drugs, Biologics, Medical Devices, Special Nutritionals, and Cosmetics). Raptiva (efalizumab). http://www.fda.gov/medwAtch/safety/2008/safety08.htm#Raptiva (accessed November 25, 2008).
22. Bongartz T., Sutton A.J., Sweeting M.J., et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295 (2006) 2275-2285